NCT05605665View on ClinicalTrials.gov

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

December 30, 2023

Study Completion Date

March 31, 2024

Conditions
Sjögren's Syndrome
Interventions
DRUG

low-dose interleukin-2

low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.

DRUG

rapamycin

Rapamycin 0.5ml was taken orally once per day

Trial Locations (1)

100044

Peking university people's hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER